NCT00967343View on ClinicalTrials.gov

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Myeloid LeukemiaLymphoblastic LeukemiaLymphomaMultiple MyelomaMyelodysplastic SyndromeMyeloproliferative Disorders
Interventions
BIOLOGICAL

Donor lymphocyte preparation depleted of host functional alloreactive T-cells

Single intravenous infusion with 2x10E6 T-cells/kg

Trial Locations (15)

1000

Université Libre de Bruxelles - Institute Jules Bordet, Brussels

3000

Universitair Ziekenhuis Gasthuisberg, Leuven

4000

University of Liege - CHU Sart Tilman, Liège

8000

Algemeen Ziekenhuis Sint-Jan, Bruges

24105

Universitätsklinikums Schleswig-Holstein Campus Kiel, Kiel

43210

Ohio State University, Comprehesive Cancer Center, Columbus

55101

Universitätsklinikum Mainz, Mainz

79106

Universitätsklinikum Freiburg, Medizinische UNI-Klinik, Freiburg im Breisgau

97080

Universitätsklinikum Würzburg, Würzburg

L8V 1C3

HHSC, Henderson Hospital Site, Hamilton

M5G 2M9

Ontario Cancer Institute / Princess Margaret Hospital, Toronto

H1T 2M4

Maisonneuve-Rosemont Hospital, Montreal

06123

Perugia University, Perugia

6229 HX

Academisch Ziekenhuis Maastricht, Maastricht

W12 ONN

Hammersmith Hospital, London

Sponsors

Lead Sponsor

Kiadis Pharma
All Listed Sponsors
lead

Kiadis Pharma

INDUSTRY

NCT00967343 - Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | Biotech Hunter | Biotech Hunter